Clinical Trial

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-15.
Trial Details
NCT Number NCT07538583
Lead Sponsor Quoin Pharmaceuticals
Conditions Netherton Syndrome
Enrollment 16 participants
Start Date 2026-03-19
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21